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Calpain 1 Knockdown Improves Tissue Sparing
and Functional Outcomes after Spinal Cord Injury in Rats
Chen Guang Yu, Yanzhang Li, Kashif Raza, Xin Xin Yu, Sarbani Ghoshal, and James W. Geddes

Abstract

To evaluate the hypothesis that calpain 1 knockdown would reduce pathological damage and functional deficits after
spinal cord injury (SCI), we developed lentiviral vectors encoding calpain 1 shRNA and eGFP as a reporter (LV-CAPN1
shRNA). The ability of LV-CAPN1 shRNA to knockdown calpain 1 was confirmed in rat NRK cells using Northern and
Western blot analysis. To investigate the effects on spinal cord injury, LV-CAPN1shRNA or LV-mismatch control
shRNA (LV-control shRNA) were administered by convection enhanced diffusion at spinal cord level T10 in Long-Evans
female rats (200–250 g) 1 week before contusion SCI, 180 kdyn force, or sham surgery at the same thoracic level.
Intraspinal administration of the lentiviral particles resulted in transgene expression, visualized by eGFP, in spinal tissue at
2 weeks after infection. Calpain 1 protein levels were reduced by 54% at T10 2 weeks after shRNA-mediated knockdown
(p < 0.05, compared with the LV-control group, n = 3 per group) while calpain 2 levels were unchanged. Intraspinal
administration of LV-CAPN1shRNA 1 week before contusion SCI resulted in a significant improvement in locomotor
function over 6 weeks postinjury, compared with LV-control administration (p < 0.05, n = 10 per group). Histological
analysis of spinal cord sections indicated that pre-injury intraspinal administration of LV-CAPN1shRNA significantly
reduced spinal lesion volume and improved total tissue sparing, white matter sparing, and gray matter sparing ( p < 0.05,
n = 10 per group). Together, results support the hypothesis that calpain 1 activation contributes to the tissue damage and
impaired locomotor function after SCI, and that calpain1 represents a potential therapeutic target.
Key words: behavior; gene therapy; lentiviral; locomotor; pathology; RNAi; tissue sparing

Introduction

T

he locomotor deficits resulting from traumatic spinal cord
injury (SCI) are the result of both the initial mechanical insult
as well as a cascade of secondary mechanisms that exacerbate the
tissue damage. Excessive calpain activation is one secondary
mechanism strongly implicated in the secondary neuronal and axonal degeneration after SCI.1 Calpains are calcium activated neutral proteases that cleave a wide range of cellular proteins including
cytoskeletal, membrane-bound, and soluble proteins.2 Loss of
function of these calpain substrates contributes to the death of
neurons and oligodendrocytes, axonal demyelination and degeneration, and locomotor deficits after SCI.3,4 In addition, calpains
serve essential physiological roles including signal transduction,
cell migration, membrane fusion, and cell differentiation.5–7 The
challenge is to prevent the excessive calpain activity that leads to
neurodegeneration, but retain the essential physiological roles of
calpains.
Of the 15 mammalian calpain isoforms identified to date, the
best characterized calpains in the central nervous system (CNS) are

the ubiquitous m- and l-calpains. These are heterodimers consisting
of a unique 80 kDa large subunit (calpain 1 and 2) and a common
28 kDa small subunit (calpain small subunit 1, also referred to as
calpain 4). The two calpain isoforms share many properties. Both are
cytosolic and appear to have similar substrate specificities, with the
major difference being that purified m-calpain requires mM Ca2 + for
activation while l-calpain requires lM Ca2 + .8 Knockout of calpain 2
is embryonically lethal, while calpain 1 null mice are viable with
minimal phenotype.9,10 In addition, CNS calpain 1 expression increases post-natally while calpain 2 expression is relatively constant
during rat CNS development and maturation.11 Together, the above
results suggest that knocking down or inhibiting calpain 1 might limit
the damage caused by excessive calpain activity, and that by targeting only a single calpain isoform that essential physiological roles
of calpains would be preserved.
In the present study, we examined the hypothesis that decreased
calpain 1 will attenuate secondary tissue damage and locomotor
deficits after contusive injury to the spinal cord. Calpain 1 levels
were reduced using lentiviral CAPN1 short hairpin ribonucleic acid
(shRNA) injected into the rat spinal cord. Because of the relatively
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rapid calpain activation that occurs after SCI compared with the
several days needed for knockdown of calpain protein levels using
RNA interference or antisense approaches,12,13 it was necessary to
administer the lentiviral CAPN1 siRNA 1 week pre-injury. Locomotor function, lesion volume, and tissue sparing were evaluated
post-injury. The longer range goal is to evaluate the potential of
CAPN1 inhibition as a druggable target.
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fluency, then infected with 105 TU/well in six-well plates. Five
days after lentiviral infection, the cells were harvested for Northern
or Western blotting. NRK cells were chosen because they express
relatively high levels of both calpain 1 and calpain 2.11 NRK cells
were assigned to the following groups: (A) Lentiviral CAPN1
shRNA and (B) Lentiviral control shRNA. Northern blotting and
Western blotting were used to evaluate the relative levels of calpain
1 mRNA and protein at 5 days post-lentiviral infection, respectively (n = 3/group).

Methods
Calpain 1 shRNA

Animals and surgical procedures

Calpain 1 (CAPN1) small interfering RNA (siRNA) sequences
(Genebank accession number: NM_019152) were selected and
chemically modified based on accepted criteria for the rational
design of siRNA with off-target control using two web-based
programs (Dharmacon and Invitrogen).14 To minimize the potential
off-target effects of siRNA, the CAPN1 siRNA sequence 1 (Sense,
start 5¢-GCACAAUCAGAGCACUUUAUC-3¢), the CAPN1
siRNA sequence 2 (Sense, start 5¢-GGGACUUCAUACGUGAG
UUCA-3¢), and mismatch control siRNA (5¢-GCAGAAUCAC
AGCACUUUAUC-3¢) were subjected to BLAST analysis and
synthesized in the modification option with off-target control by
Thermo Scientific-Dharmacon Products (Lafayette, CO). To determine the efficacy of CAPN1 siRNA sequences, normal rat kidney
(NRK) cells (3 · 105/well in 6-well plates) were transfected with
100 nM calpain 1 siRNAs complexed with Lipofectamine 2000,
based on the manufacturer’s instructions (Invitrogen, Carlsbad, CA).
NRK cells were assigned to the following groups: (A) mismatch
control siRNA 1 transfection, (B) negative control siRNA transfection, (C) calpain 1 siRNA1 transfection, and (D) calpain 1 siRNA 2
transfection. Western blot analysis was used to evaluate the relative
levels of calpain 1 or calpain 2 protein at 48 h post-transfection
(n = 4/group).
NRK cells were purchased from American Type Culture Collection (ATCC, Manassas, VA) and maintained in Dulbecco
modified eagle medium supplemented with 5% fetal bovine serum,
10% heat-inactivated donor horse serum, 50 lg/mL streptomycin,
and 50 IU/mL penicillin in a humidified atmosphere at 37C and
5% CO2 as described in the protocol provided by ATCC.

Thirty-two female Long-Evans adult rats (Charles River, Indianapolis, IN) weighing 200–250 g were used for the in vivo experimental studies. All experimental procedures were approved and
performed in accordance with the Guidelines of the US National
Institutes of Health and Institutional Animal Care and Use Committee of the University of Kentucky.
Animals were kept under standard housing conditions for at least
1 week after arrival. Lentiviral particles containing LV-CAPN1shRNA and LV-control shRNA were administered by convection
enhanced delivery17,18 at spinal segment T10. Intraspinal injections
were made bilaterally at 0.5 mm lateral to the midline and 1 mm
ventral. For each injection site, a volume of 3.0 lL was slowly
administered over 30 min.
Contusive SCI was produced after a T10 laminectomy using an
Infinite Horizons (IH) spinal cord injury device (Precision Systems &
Instrumentation, Fairfax Station, VA) as described previously.19,20
Briefly, adult female Long-Evans rats, weighing 200–250 g, were
anesthetized with ketamine (80 mg/kg, intraperitoneal [ip]) and
xylazine (10 mg/kg, ip), and a laminectomy was made to expose
spinal segment T10. The exposed vertebral column was stabilized
by clamping the rostral T9 and caudal T11 vertebral bodies with
two spinal forceps. SCI was then applied with the IH device using a
180 kdyn force setting, which resulted in moderately severe contusion injury. Impact analyses, including actual force applied to the
spinal cord, displacement of spinal cord, and velocity, were recorded. The impact tip was automatically retracted immediately,
the wound irrigated with saline, and the muscle and skin openings
were closed with sutures. The surgical procedure and postoperative
care were similar to that described previously.19

Lentiviral vectors

Northern blot analysis

Lentiviral vectors were chosen because they induce little or no
immune response within the host, they provide long-lasting transgene expression, and they infect dividing and non-dividing cells
including neurons and glia.15,16
LentiLox 3.7 vector16 was purchased from ATCC (pLL3.7,
Manassas, VA). It contains a cytomegalovirus (CMV) promoter
driven enhanced green fluorescent protein (eGFP) reporter and a
U6 promoter with downstream of cloning sites (HpaI and XhoI) to
allow the introduction of oligonucleotides encoding CAPN1
shRNA or mismatch control shRNA to produce LV-CAPN1shRNA
or LV-control shRNA. The LV-CAPN1shRNA or LV-control
shRNA was cotransfected with packaging plasmid PAX2 and
envelope plasmid pMD2G (obtained from Dr. Didier Trono,
University of Geneva, Switzerland) into 293FT cells (Invitrogen)
using calcium-phosphate precipitate. Viral supernatants were
harvested and concentrated after 72 h. The titer of the lentiviral
stocks was assessed by using 10-fold serial dilutions to transducer
HT 1080 human fibrosarcoma cells (ATCC) using the eGFP reporter of the pLL3.7 vector to identify infected cells. The viral
titer was 5 · 107 to 1 · 108 TU/mL for LV-CAPN1shRNA and
LV-control shRNA.
Knockdown of calpain 1 mRNA and protein in the NRK cells
treatment was determined using Northern blot and Western blot
analysis, respectively. The NRK cells were grown to 80% con-

Lentivirus-infected NRK cells were lysed with Trizol reagent
(Invitrogen) and prepared for total RNA isolation according to the
manufacturer’s instructions. 1.0 lg of total RNA was fractioned on
a 10% denaturing polyacrylamide gel and transferred to a nitrocellulose membrane. Blots were hybridized to a probe consisting of
a 5¢ digoxin-labeled 21-nt calpain 1 siRNA sense strand (DIG RNA
Labelling Kit, Roche Applied Science, Mannheim, Germany). A 5¢
digoxin-labeled actin probe was used to determine equal loading of
RNA. The hybridization and the detection of the hybridized probe
were performed according to DIG Application Manual (Roche
Applied Science, Mannheim, Germany).
Western blot analysis
NRK cells were washed with 1 · phosphate buffered saline
(PBS), lysed by adding buffer, and sonicated for 15 sec to shear
deoxyribonucleic acid and reduce sample viscosity. For spinal cord
samples, animals were euthanatized by pentobarbital (100 mg/kg,
ip injection) and decapitated 2 weeks post-injury. A 5-mm block of
spinal cord centered on T10 was removed and snap-frozen on dry
ice, then stored at - 80C. The spinal cord samples were homogenized in a lyses buffer and sonicated. The protein samples were
obtained by microcentrifugation at 14,000 rpm for 10 min. Protein
quantities were determined using the bicinchoninic method.

LENTIVIRAL CALPAIN 1 SHRNA THERAPY FOR SCI
Western blotting was performed as described previously.21,22
Briefly, NRK cell protein samples or spinal cord protein samples
were loaded on SDS-PAGE gels and electrotransferred to nitrocellulose membranes. Blots from cell samples or spinal cord
samples were probed with a polyclonal anti-rabbit antibody against
calpain 1 (1:1000, Chemicon, Temecula, CA). Blots were then
incubated with infrared-labeled anti-rabbit secondary antibody
(1:5000). The blots were reprobed with a monoclonal anti-mouse
antibody against actin (1:1000, Chemicon, Temecula, CA) and then
incubated with infrared-labeled anti-mouse secondary antibody
(1:5000). All blots were visualized and analyzed on the LI-COR
Odyssey infrared imaging system (Lincoln, NE).
Immunofluorescence imaging
At 2 weeks post-injection with LV-CAPN1shRNA and LVcontrol shRNA, rats were transcardially perfused with cold saline
followed by buffered 4% paraformaldehyde. The spinal cord was
removed, cut into blocks according to the segments, and postfixed
with the same fixative overnight. The fixed spinal cords were serially and transversely cryosectioned at 20 lm. eGFP expression
was viewed using a fluorescence microscopy system (Olympus
DSU) (n = 3/group).
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participating in the BBB evaluation were blinded to the experimental treatment received by each animal.
Assessment of tissue sparing
At 6 weeks post-injury, animals were euthanatized and transcardially perfused with cold saline followed by buffered 4%
paraformaldehyde. The spinal cord was removed and prepared for
histological assessment as described previously.19,24 Spinal cords
were serially and transversely cryosectioned at a thickness of
20 lm. Every fifth section was mounted onto gelatin-coated slides
and stored at - 20C. A modified eriochrome cyanine staining
protocol for myelin that differentiates both white matter and cell
bodies was used to visualize spared spinal tissue. Area measurements in lesion, gray matter, white matter, and total spinal tissue
and calculation of lesion volume, total tissue sparing, white matter
sparing, and gray matter sparing in transverse sections of the injured cords were performed as described previously.19,24

Assessment of locomotor function
Open-field locomotor function was assessed preinjury and 0, 3,
7, 14, 21, 28, 35, and 42 days post-injury using the Basso, Beattie,
Bresnahan (BBB) locomotor rating scale.19,23 The two examiners

FIG. 1. Knockdown of calpain 1 with siRNA in vitro. Two
calpain 1 siRNA sequences were evaluated in transient transfection assays. Normal rat kidney cells (3x105/well in six-well plates)
were transfected with 100 nM calpain 1 siRNA sequence 1 or
sequence 2 using lipofectamine 2000 (Invitrogen). Relative protein levels of calpain 1 (80 kDa) were measured 48 h after transfection using Western blot and compared with levels of actin.
Each siRNA sequence decreased calpain 1 levels by approximately 60%, ***p < 0.001, compared with mismatch control siRNA
and to negative control siRNA, repeated measures analysis of
variance, and Bonferroni post hoc test, n = 4 per group.

FIG. 2. Knockdown of calpain 1 with LV-CAPN1 shRNA in vitro.
Calpain 1 siRNA (sense sequence: 5¢GCACAATCAGAGCAC
TTTATC 3¢, 1462-1482 of NM_019152) or mismatch control siRNA
were inserted into the Lentilox 3.7 shRNA vector. Infection of normal rat kidney cells with LV-CAPN1 shRNA or LV-Control shRNA
was performed. The cells were grown to 80% confluency, then infected with 105 TU/well in six well plates. A reduction in Capn1 in
mRNA was evident at 5 days after lentiviral infection using Northern
blotting (A). Calpain 1 protein levels were significantly reduced in
the cells infected with LV-CAPN1 shRNA or LV-control shRNA
and were measured at 5 days after infection using Western blot
analysis (B, C). **p < 0.001, compared with control group, t test,
n = 3/group.
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Statistical analysis
Analysis was performed using StatView (SAS Institute, Cary,
NC). Data are presented as mean – standard error of the mean.
Group differences were evaluated by t test or repeated measures
analysis of variance and Bonferroni post hoc test as described
previously.25 Null hypotheses were rejected at the p < 0.05 level.
Although the BBB scale is an ordinal scale, differences between the
treatments were compared using parametric statistical methods
recommended by Scheff and colleagues.24
Results
Calpain 1 siRNA reduces calpain 1 levels in vitro
Initially, we evaluated two calpain 1 (100 nM) siRNAs (n = 4/
group) in NRK cells (3 · 105/well in six-well plates), measuring
calpain 1 or calpain 2 levels by Western blotting 48 h after transfection (Fig. 1). Both siRNAs significantly reduced calpain 1 levels
while a negative control and mismatch control that differed from
the calpain 1 siRNA sequence 1 by a single nucleotide (see
Methods) did not significantly alter calpain 1 levels. Calpain1
siRNA 1 did not decrease calpain 2 levels (Fig. 1).
LV-CAPN1 shRNA reduces calpain 1 in vitro
At 5 days after transient transfection of NRK cells with LVCAPN1shRNA or LV-control shRNA (n = 3/group), LV-CAPN1shRNA significantly decreased levels of calpain 1 mRNA (Fig. 2A)
and protein (Fig. 2B, 2C) by 80% at 5 days after viral infection in
NRK cells compared with LV-control shRNA infection.
LV-CAPN 1 shRNA reduces calpain 1 expression in vivo

FIG. 3. Knockdown of calpain 1 with LV-CAPN1 shRNA
in vivo (A): Intraspinal diffusion of LV-CAPN1 shRNA by convection enhanced delivery (unilateral injection at T10) resulted in
ipsilateral eGFP expression in the spinal cord at injection epicenter and 2 mm rostral and 2 mm caudal to the injection epicenter
2 weeks post-infection in naı̈ve rats, compared to PBS diffused
control. The intraspinal administration of LV-CAPN1 shRNA
resulted in reduced levels of calpain 1 (B, C), but not calpain 2
(B,D), at two weeks post-injury, *p < 0.05.

Table 1. Injury Parameters
Treatment
group
LV-Control
shRNA
LV-CAPN1
shRNA

Actual
force
(kdyn)

Displacement
(microns)

Velocity
(mm/sec)

182 – 2

832 – 79

122 – 0.4

180 – 2

995 – 89

122 – 0.3

Values are mean – standard error of the mean. No significant differences
in impact force, displacement, and velocity were found between the
treatment groups (n = 10/group).

After intraspinal administration via convection enhanced delivery, expression of LV-CAPN1shRNA was examined by direct
visualization of eGFP with fluorescent microscopy (Fig. 3A). Intraspinal delivery of LV-CAPN 1 shRNA (n = 3/group) resulted in
eGFP expression in the spinal cord 2 mm rostral and 2 mm caudal to
the injection site at 2 weeks post-injection.
Western blot analysis demonstrated that intraspinal administration of LV-CAPN1shRNA (n = 3/group) reduced calpain 1 protein
levels by 54% but did not have a significant effect on calpain 2 (Figs
3B–D).
Lentiviral-CAPN1 shRNA improves locomotor function
6 weeks after contusive SCI in rats
No significant differences in actual force, displacement, or velocity were found between LV-CAPN1shRNA and LV-control
groups, indicating similar injuries to all animals (Table 1).
Immediately after SCI, all animals exhibited complete bilateral
hindlimb paralysis. Behavioral assessment demonstrated that rats
receiving LV-CAPN1shRNA exhibited improved locomotor performance as early as 3 days post-injury, compared with rats receiving the LV-control shRNA, and the improvement persisted
until the last observation at 6 weeks post-injury, (Fig. 4, n = 10/
group). At 6 weeks post-injury, the rats treated with LVCAPN1shRNA had a mean BBB score of 12.4, indicative of
frequent to consistent weight-supported plantar steps and occasional to frequent front limb-hind limb coordination.23 Rats administered LV-control shRNA had a mean BBB score of 9 at 6
weeks post-injury, indicative of plantar placement of the paw with
weight support in stance only, but without weight-supported plantar
stepping.

LENTIVIRAL CALPAIN 1 SHRNA THERAPY FOR SCI
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sulted in a decrease in lesion volume (Fig. 5) and significant increase in total tissue sparing, white matter sparing, and gray matter
sparing (Fig. 6). The tissue sparing was evident up to 5 mm both
rostral and caudal to the lesion epicenter at 6 weeks post-injury
compared with animals receiving LV-control shRNA (n = 10/
group).
Discussion

FIG. 4. LV-CAPN1 shRNA improves locomotor function fter
spinal cord injury (SCI). Pre-injury administration of LV-CAPN1
shRNA (triangles) resulted in improved locomotor performance
compared with LV-contro–pretreated animals (circles). Contusive
SCI was produced using the Infinite Horizons Impactor, 180 kdyn
setting, at T10. Data were presented as mean – standard error of
the mean and analyzed with repeated measures analysis of variance followed by Bonferroni post hoc analysis, *p < 0.05.
Lentiviral-CAPN1 shRNA attenuates lesion
volume and improves tissue sparing at 6 weeks
after contusive SCI
Histological assessment of lesion volume and tissue sparing
showed that intraspinal administration of LV-CAPN1shRNA re-

Knockdown of calpain1 in the rat spinal cord by lentiviral
shRNA resulted in a significant attenuation in lesion volume and
improvement in tissue sparing and locomotor function after contusive SCI. Although pre-injury administration of lentiviral particles is not feasible from a therapeutic standpoint, this approach
enabled examination of the role of the calpain 1 isoform, which is
not possible using current pharmacologic inhibitors. The results
support the hypothesis that calpain 1 activation contributes to the
tissue damage and impaired locomotor function after SCI, and
therefore represents a potential druggable target.
The improvement in locomotor function and tissue sparing observed with calpain 1 knockdown is comparable to that observed
previously with broad-spectrum calpain inhibitors.19,26,27 This
suggests that of the several calpain isoforms present in the CNS,28
excessive activation of calpain 1 is a major contributor to the
neurodegeneration and resultant loss of motor function. Calpain 1
activation is relatively rapid after SCI,13 and the pre-injury
knockdown would be optimal for neuroprotection. This may account for the improvement in BBB scores observed as early as 3
days after injury. The early improvement in locomotor function is
consistent with pre-injury or immediate post-injury administration
of broad-spectrum small molecule calpain inhibitors.19,26,27

FIG. 5. Effects of the LV-CAPN1 shRNA pretreatment on lesion volume 6 weeks after severe contusive spinal cord injury (SCI). (A)
Photomicrographs of representative transverse spinal cord sections from rats at 42 days after contusive SCI (180 kdyn). The sections are
from the lesion epicenter and 1, 2, 4 mm rostral and caudal to the epicenter, obtained from a LV-control shRNA-treated rat (top panel)
and a LV-CAPN1-shRNA treated rat (bottom panel). The sections were stained with eriochrome cyanine for myelin. Scale bar: 100 lm.
(B) Pre-injury administration of LV-CAPN1 shRNA resulted in a significant decrease in lesion volume after contusion injury to the
spinal cord. Injury conditions and treatment groups are as described in Figure 4. Data were presented as mean – standard error of the
mean and analyzed by t test. *p < 0.05, n = 10/group.
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FIG. 6. Effects of the LV-CAPN1 shRNA pre-treatment on tissue sparing 6 weeks after severe contusive spinal cord injury. Pre-injury
administration of LV-CAPN1 shRNA resulted in a significant increase in total tissue sparing (A, B), white matter sparing (C, D), and
gray matter sparing (E, F) after contusion injury to the spinal cord. Data were analyzed by t test (A, C, E) or repeated measures analysis
of variance followed by Bonferroni post-hoc analysis (B,D,E) *p < 0.05, **p < 0.01.
Although the results support a role for calpain 1 in the secondary
injury cascade, the therapeutic window for the beneficial effects of
calpain 1 knockdown or inhibition remain to be determined.
Administration of LV-CAPN1-shRNA into the spinal cord
would be expected to knock down calpain 1 levels in the surrounding gray matter, but not in the ascending and descending
axons in the white matter whose cell bodies are distal to the areas
exposed to the lentiviral particles. Thus, the sparing observed in
white matter is unlikely to be the result of calpain 1 knockdown
within the affected axons. Excitotoxic mechanisms are implicated
in the degeneration of oligodendrocytes after SCI,29 and this is
mediated at least in part by calpain activation.30 Calpains are implicated in the demyelination associated with multiple sclerosis,
and calpain inhibitors protect the white matter in animal models of
this disorder.31,32 Thus, the white matter sparing observed with LVCapn1-shRNA is thought to reflect protection of oligodendrocytes
after SCI.
It is also of interest that the approximately 2 mm diffusion of the
LV-Capn1 shRNA in the rostral and caudal direction resulted in
improved tissue sparing of up to 6 mm in both directions after SCI.
This is consistent with calpain-mediated cell death contributing to
the increase in lesion size with time after SCI, and that early in-

tervention minimizes lesion size and maintains axon-myelin integrity, resulting in maintained motor function.1
Additional support for the hypothesis that reduced calpain 1
protects against neurodegeneration was recently provided by
Bevers and colleagues,33 who found that calpain 1 knockdown with
RNAi attenuated proteolysis of the calpain substrate spectrin after
transient forebrain ischemia minimized the loss of hippocampal
CA1 neurons and preserved electrophysiologic function. In addition, calpain 1 null mice exhibited less cortical degeneration after
traumatic brain injury.28 The neuroprotective effect of decreased
calpain 1 against neurodegeneration after SCI had not been examined previously.
The results also demonstrate that convection enhanced delivery is an effective delivery method for lentiviral particles in the
rat spinal cord. Convection enhanced delivery is the use of a
slight pressure gradient during interstitial infusion to augment
diffusion and increase the distribution of both small and large
molecular weight molecules, including proteins.17 Intraspinal
administration of LV-CAPN1shRNA via convection enhanced
delivery provided rostral and caudal spread away from the injection site, leading to a significant reduction in protein expression in the spinal cord.

LENTIVIRAL CALPAIN 1 SHRNA THERAPY FOR SCI
Conclusion
The results demonstrated efficient lentiviral gene transfer of a
calpain1 shRNA through convection enhanced delivery in the
spinal cord of rats. Lentiviral calpain 1 shRNA administration
provided effective calpain 1 knockdown and resulted in improvement in both tissue sparing and locomotor function, suggesting that
reduced calpain 1 activity is neuroprotective against SCI and represents a promising therapeutic target for SCI.
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